#USA #Seattle #Curta #Jens Grueger #health economics

Curta Welcomes a New Leader in Global Market Access

Curta, a prominent player in strategy and evidence generation within the life sciences, has announced a significant addition to its advisory team. Dr. Jens Grueger, a respected authority in health economics and market access, has joined the company as Senior Advisor for Global Evidence, Value, Pricing, and Access Strategies, effective May 1, 2025. This strategic hire signals Curta's ambition to reinforce its global position and enhance its capabilities in helping life sciences companies navigate the complexities of commercialization and market access.

Dr. Grueger brings over four decades of experience in the pharmaceutical industry, making him a valuable asset to Curta. His career spans high-ranking roles at major pharmaceutical powerhouses such as Roche, Pfizer, and Novartis, where he specialized in global market access and pricing strategies. Notably, he served as the Senior Vice President and Head of Global Access at Roche from 2011 to 2019, a role that positioned him at the forefront of market access strategies amidst a rapidly evolving healthcare landscape.

In his previous positions, Dr. Grueger pioneered the implementation of value-based pricing frameworks, including innovative risk-sharing and performance-based models tailored to improve patient access to novel therapies. His recent tenure at the Boston Consulting Group as a Director and Partner further solidified his expertise, where he guided clients through the intricacies of pricing and market access in the life sciences sector.

Dr. Sean Sullivan, Curta's President, emphasized the significance of this appointment, stating, “Jens Grueger brings unparalleled expertise in global market access and value-based pricing—critical areas as the healthcare landscape grows increasingly complex. His leadership will enhance Curta's ability to deliver strategic guidance that accelerates commercialization and optimizes market success for our clients.” This highlights the importance of aligning innovative therapies with market access strategies that meet regulatory and payer expectations.

Curta aims to leverage Dr. Grueger's extensive knowledge and insights to ensure that the products developed by their partnered life sciences companies reach the patients who need them most. With continuing advancements in healthcare innovations, the role of effective market access strategies cannot be overstated, and Curta's commitment to this area is evident in its strategic hires and operational focus.

Dr. Lisa Bloudek, CEO of Curta, expressed her enthusiasm about the new partnership, stating, “We are honored to welcome Jens Grueger as an expert advisor. His proven leadership in global access and pricing will expand our ability to deliver high-impact strategies that drive market success and long-term value for our clients.” This partnership not only aims to enhance Curta's positioning in the marketplace but also reflects its dedication to providing solutions that address the numerous challenges faced by healthcare stakeholders.

Curta’s approach is rooted in solid scientific integrity, where they specialize in evidence generation to support health policy, market access, and commercialization teams. Their methodologies include economic modeling, real-world data analytics, and digital health strategies, which together help demonstrate the value of products within a global context. As a partner-owned organization, Curta can develop bespoke approaches that cater to the specific needs of biopharma companies while adapting to the ever-evolving payer landscapes.

In closing, Dr. Grueger's appointment marks a significant milestone for Curta as they channel his extensive experience into enriching their service offerings. This strategic move is expected to enhance Curta’s commitment to driving market access success and supporting life sciences companies in their mission to deliver innovative solutions to healthcare challenges worldwide.